---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-23-000004"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2023-02-01T23:59:59+00:00"
generated_at: "2026-06-20T04:37:18.002298+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific Q4 rev $3.24B (+3.7% reported); adj. EPS $0.45 flat YoY; guides FY23 adj. EPS $1.86-$1.93

## Summary
- Q4 net sales $3.242B, up 3.7% reported, 7.1% organic; GAAP EPS $0.09 ($126M net income), adj. EPS $0.45.
- FY22 net sales $12.682B (+6.7% reported); GAAP EPS $0.45; adj. EPS $1.71 vs $1.63 prior year.
- FY23 guidance: reported sales growth 5-7%, organic 6-8%; adj. EPS $1.86-$1.93; Q1 adj. EPS $0.42-$0.44.
- Cardiovascular segment Q4 sales +6.4% reported; MedSurg +4.4% reported; US sales +10.5%.
- Agreed to acquire Apollo Endosurgery and majority stake in Acotec Scientific; AGENT DCB approved in Japan.

## SEC filing metadata
- accession: 0000885725-23-000004
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2023-02-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572523000004/0000885725-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572523000004/bsx-20230201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-23-000004
- JSON: https://secwatch.observer/filing/0000885725-23-000004.json
- Plain text: https://secwatch.observer/filing/0000885725-23-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.